Lugano, Switzerland, 22 September 2014 – Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014.

Helsinn has awarded a grant to prIME oncology, a global professional Independent Medical Education organization specializing in educational activities for physicians who treat patients with cancer. prIME oncology has developed an education program for ESMO 2014 designed to improve the understanding of the basic physiology of chemotherapy-induced nausea and vomiting (CINV) and the mechanisms of action of the currently used different classes of antiemetic agents. The symposium will help to create a better appreciation of the treatment and patient variations that underpin CINV and the therapeutic options recommended by international guidelines that should be applied in routine clinical practice. It will also raise awareness of the appropriate strategies to individualize antiemetic therapy and incorporate the latest information on effective, convenient and well-tolerated antiemetic regimens for both moderately and highly emetogenic chemotherapy.

Helsinn’s Chief Executive Officer, Mr. Riccardo Braglia, commented: “Helsinn is delighted to support this symposium, which is designed to raise awareness and understanding of oncologists and healthcare providers around the world about the advances in tackling CINV, one the most challenging side-effects of cancer and cancer treatment. This reaffirms our resolute commitment to building better today for people with cancer, today, now, when it counts.”

The satellite symposium will take place in conjunction with the ESMO 2014 Congress at IFEMA, Madrid, Spain, on Friday, 26th September 2014, from 15:00-17:00 in the San Sebastian Auditorium. It will involve a mixture of didactic lectures and case-based discussions with audience participation. Recent clinical trial data and strategies for optimizing antiemetic therapy in the clinical setting and minimizing adverse events will be highlighted using case-based scenarios discussed by the faculty: Pascale Dielenseger, Dr. Richard Gralla and Dr. Karin Jordan. The symposium will be chaired by Dr. Matti Aapro. This will be a Webcast event with presentation slides available at, with over 1,000 international medical oncologists and healthcare providers expected to join.

For more information, please contact:

Helsinn Group

Paola Bonvicini

Head of Communication & Press Office

Tel: +41 91-985-21-21

[email protected]

For media/external inquiries

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Laura Thornton

Tel: +44 (0)203 709 5700

[email protected]

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in-licenses early‐to‐late stage new chemical entities to complete their development through the performance of preclinical/ clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out‐licensed to its network of local marketing and commercial partners, selected for their deep in‐market knowledge and know‐how, whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers.

In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.

Further information on Helsinn Group is available at

<< Back